DNA X (SONM) Stock Price

DNA X Price

NASDAQ·CLOSED
3.19
​
Market closed

Over the last 24 years DNA X grew revenue by 13.4% annually, reaching 58.30 M USD. For DNA X, the net margin of -57.7% is down versus -46.8% a few years ago. The consensus 12-month price target for DNA X is 2.04 USD, about 36.2% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

DNA X stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DNA X business model & stock analysis

Sonim Technologies, Inc. engages in the design and manufacture of mission-critical smart phone-based solutions for workers in extreme, hazardous, and isolated environments. The company is headquartered in Austin, Texas and currently employs 403 full-time employees. The company went IPO on 2019-05-10. The company provides its solutions under three categories: ultra-rugged mobile phones based on the Android platform, which are capable of attaching to both public and private wireless networks; industrial-grade accessories; and cloud-based software and application services. Its devices include Sonim XP8, Sonim XP5s and Sonim XP3. Sonim XP8 is an Android-based long-term evolution (LTE) smartphone. Sonim XP5s is a purpose-built LTE feature phone. Sonim XP3 is an LTE feature phone. The firm serves the construction, energy and utility, hospitality, logistics, manufacturing, public sector and transportation sectors.

Frequently asked questions about DNA X

Analysts currently set an average price target of 2.04 USD for the DNA X stock (median: 2.04 USD), implying -36.2 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the DNA X stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect DNA X to generate revenue of 143.20 M USD and earnings per share of 20.00 USD.

Converted at the current exchange rate, the DNA X share trades at 2.85 EUR (3.19 USD).

The DNA X share (SONM) is listed on 1 stock exchanges, including: NASDAQ (SONM).

The expected revenue of DNA X is 143.20 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of DNA X is 29.77 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of DNA X is currently 0.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DNA X stock.

The price-to-sales ratio (P/S) of DNA X is currently 0.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DNA X stock.

The Eulerpool Quality Score for DNA X is 1/10.

The ISIN of DNA X is US83548F4081. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of DNA X is A2PH9U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of DNA X is SONM. The ticker symbol is used to trade DNA X shares on the stock exchange.

Fair ValueTerminal
2.97 USD
Over-/UndervaluationTerminal
Fairly valued
Industry
Technology Hardware, Storage & Peripherals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
May 10, 2019
ISIN
US83548F4081
Cusip
83548F101
Sedol
BJLD0W2
Market capitalization
4.76 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
0.16
P/S
P/Se
0.03
EV/EBIT
—
P/B Ratio
0.21
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1,242.90 %
Last updated Oct 25, 2026, 3:48 AM

All fundamentals and in-depth analysis of DNA X

Our stock analysis for DNA X stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DNA X. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.